临床试验/NCT01606995

NCT01606995已完成不适用

Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation

Bayer0 个研究点目标入组 6,784 人开始时间: 2012年6月12日最近更新: 2022年8月3日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Bayer
入组人数: 6,784
主要终点: Safety variables will be summarized using descriptive statistics based on adverse events collection

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study

排除标准

未提供

研究组 & 干预措施

Group 1

干预措施: Rivaroxaban (Xarelto, BAY59-7939) (Drug)

结局指标

主要结局

Safety variables will be summarized using descriptive statistics based on adverse events collection

时间窗: after 1 year or until 30 days after end of rivaroxaban therapy

Adjudicated major bleeding events

时间窗: after 1 year or until 30 days after end of rivaroxaban therapy

次要结局

All cause mortality(after 1 year or until 30 days after end of rivaroxaban therapy)
Persistence with rivaroxaban treatment: Reasons for any switch from or interruption of rivaroxaban treatment(after 1 year or until 30 days after end of rivaroxaban therapy)
Adjudicated symptomatic thromboembolic events(after 1 year or until 30 days after end of rivaroxaban therapy)

研究者

发起方

Bayer

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

不适用

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in AsiaAtrial Fibrillation

NCT01750788Bayer2,297

已完成

不适用

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional StudyStroke

NCT02784717Bayer3,055

已完成

不适用

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial FibrillationAtrial Fibrillation

NCT03284762Bayer1,216

已完成

不适用

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA RegionAtrial Fibrillation

NCT01800006Bayer2,101

已完成

不适用

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial FibrillationNon-valvular Atrial Fibrillation (NVAF)

NCT03746301Bayer924